Financial reports
ARS
2023 FY
Annual report to shareholders
15 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
20 Mar 24
8-K
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
7 Mar 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Other Events
15 Nov 23
8-K
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
7 Nov 23
8-K
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
7 Nov 23
8-K
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
26 Sep 23
8-K
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
9 Aug 23
8-K
Lumos Pharma Announces Departure of Chief Medical Officer
28 Jun 23
8-K
Lumos to Highlight New LUM-201 Data and Analysis Presented
21 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Aug 22
S-3
Shelf registration
18 Aug 22
S-8
Registration of securities for employees
27 Aug 21
424B5
Prospectus supplement for primary offering
30 Dec 20
424B3
Prospectus supplement
10 Aug 20
S-3
Shelf registration
28 Jul 20
RW
Registration withdrawal request
10 Jul 20
S-3
Shelf registration
12 Jun 20
S-8
Registration of securities for employees
7 Apr 20
S-8
Registration of securities for employees
12 Nov 19
Proxies
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
DEFA14A
Additional proxy soliciting materials
23 Mar 22
DEF 14A
Definitive proxy
23 Mar 22
DEFA14A
Additional proxy soliciting materials
6 Apr 21
DEF 14A
Definitive proxy
6 Apr 21
DEF 14A
Definitive proxy
23 Jun 20
DEFA14A
Additional proxy soliciting materials
6 Mar 20
Other
EFFECT
Notice of effectiveness
29 Aug 22
CORRESP
Correspondence with SEC
24 Aug 22
UPLOAD
Letter from SEC
23 Aug 22
EFFECT
Notice of effectiveness
10 Aug 20
UPLOAD
Letter from SEC
5 Aug 20
CORRESP
Correspondence with SEC
5 Aug 20
CORRESP
Correspondence with SEC
4 Feb 20
UPLOAD
Letter from SEC
4 Feb 20
UPLOAD
Letter from SEC
3 Feb 20
CORRESP
Correspondence with SEC
28 Jan 20
Ownership
4
BRADLEY J POWERS
3 Apr 24
4
Lori D Lawley
3 Apr 24
4
Pisit Duke Pitukcheewanont
3 Apr 24
4
John C. McKew
3 Apr 24
4
Richard J Hawkins
3 Apr 24
4
Aaron Schuchart
3 Apr 24
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Feb 24
4
John C. McKew
7 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13G
WELLS FARGO & COMPANY/MN
6 Feb 24